Dermatology Unit, University of Campania "Luigi Vanvitelli", Naples, Italy.
Department of Anesthesiology, Surgery and Emergency, University of Campania "Luigi Vanvitelli", Naples, Italy.
Dermatol Ther. 2019 May;32(3):e12858. doi: 10.1111/dth.12858. Epub 2019 Feb 28.
Psoriasis is a common, chronic, immune-mediated disease occurring more frequently in association with comorbid metabolic disorders. The management of patients with multiple organ dysfunction is challenging since the use of all conventional systemic agents is limited or contraindicated. In the last two decades, the introduction of biological drugs has revolutionized treatment paradigms of psoriasis and enabled numerous patients to achieve disease control with an acceptable safety profile. We reported for the first time the case of a 66-year-old female psoriatic patient affected by myocardial infarction, hypertension, chronic renal failure, hyperthyroidsm and morbid obesity, who experienced remarkable improvement in skin and joint synthoms and metabolic parameters after 48 weeks of secukinumab monotherapy. In our patient, secukinumab was well tolerated and no side effects have been observed. Our observation suggests that secukinumab could be a safe therapeutic option in patients with organ impairment or failure in which the majority of conventional systemic agents are contraindicated.
银屑病是一种常见的慢性免疫介导性疾病，常与合并的代谢紊乱相关。由于所有常规系统药物的使用受到限制或禁忌，因此管理多器官功能障碍的患者具有挑战性。在过去的二十年中，生物药物的引入彻底改变了银屑病的治疗模式，使许多患者能够以可接受的安全性控制疾病。我们首次报道了一例 66 岁女性银屑病患者的病例，该患者患有心肌梗死、高血压、慢性肾衰竭、甲状腺功能亢进和病态肥胖，在接受司库奇尤单抗单药治疗 48 周后，皮肤和关节症状以及代谢参数显著改善。在我们的患者中，司库奇尤单抗耐受良好，未观察到不良反应。我们的观察结果表明，在大多数常规系统药物禁忌的器官损伤或衰竭的患者中，司库奇尤单抗可能是一种安全的治疗选择。
